Identification of Circulating MicroRNAs as Potential Biomarkers for Detecting Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The disease is characterized by various cytogenetic and molecular abnormalities with distinct prognoses and gene expression profiles. Emerging evidence has suggested that circulating microRNAs (miRNAs) could serve as noninvasive biomarkers for cancer detection; however, little is known about circulating miRNA profiles in AML patients. In this study, a genome-wide serum miRNA expression analysis was performed using Solexa sequencing for initial screen, followed by validation with real-time PCR assays. The analysis was conducted on training and verification sets of serum samples from 140 newly diagnosed AML patients and 135 normal adult donors. After a two-phase selection and validation process, 6 miRNAs, miR-10a-5p, miR-93-5p, miR-129-5p, miR-155-5p, miR-181b-5p and miR-320d, were found to have significantly different expression levels in AML compared with control serum samples. Furthermore, unsupervised clustering analysis revealed the remarkable ability of the 6-miRNA profile to differentiate between AML patients and normal controls. The areas under the ROC curve for the selected miRNAs ranged from 0.8129 to 0.9531. More importantly, miR-181b-5p levels in serum were significantly associated with overall survival. These data demonstrated that the expression patterns of circulating miRNAs were systematically altered in AML and miR-181b-5p may serve as a predictor for overall survival in AML patients.

[1]  Torsten Haferlach,et al.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin , 2008, Proceedings of the National Academy of Sciences.

[2]  R. Hills,et al.  Independent prognostic variables in acute myeloid leukaemia. , 2011, Blood reviews.

[3]  Hongxia Wang,et al.  MicroRNA expression profile of colon cancer stem-like cells in HT29 adenocarcinoma cell line. , 2011, Biochemical and biophysical research communications.

[4]  Xu Ma,et al.  MicroRNA‐181b and microRNA‐9 mediate arsenic‐induced angiogenesis via NRP1 , 2012, Journal of cellular physiology.

[5]  M. Caligiuri,et al.  FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Blood.

[6]  Juergen Thiele,et al.  The 2008 World Health Organization classification system for myeloproliferative neoplasms , 2009, Cancer.

[7]  K. Guo,et al.  miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. , 2012, Biochemical and biophysical research communications.

[8]  Sam Griffiths-Jones,et al.  The microRNA Registry , 2004, Nucleic Acids Res..

[9]  Wei Xu,et al.  Distinctive microRNA signature is associated with the diagnosis and prognosis of acute leukemia , 2012, Medical Oncology.

[10]  K. Zen,et al.  Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers , 2012, Medicinal research reviews.

[11]  J. Gimferrer,et al.  Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer , 2012, European Respiratory Journal.

[12]  M. Caligiuri,et al.  MicroRNA expression in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[13]  Michael J Kerin,et al.  MicroRNAs as Prognostic Indicators and Therapeutic Targets: Potential Effect on Breast Cancer Management , 2008, Clinical Cancer Research.

[14]  Ron Kohavi,et al.  A Study of Cross-Validation and Bootstrap for Accuracy Estimation and Model Selection , 1995, IJCAI.

[15]  X. Chen,et al.  Identification of ten serum microRNAs from a genome‐wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis , 2011, International journal of cancer.

[16]  Bob Löwenberg,et al.  MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. , 2008, Blood.

[17]  Fang Wang,et al.  miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia , 2011, Molecular Biology Reports.

[18]  T. Davison,et al.  miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. , 2011, Experimental hematology.

[19]  Stefano Volinia,et al.  miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. , 2011, Blood.

[20]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Tohru Mochizuki,et al.  Let-7 MicroRNA Family Is Selectively Secreted into the Extracellular Environment via Exosomes in a Metastatic Gastric Cancer Cell Line , 2010, PloS one.

[22]  Xi Chen,et al.  A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. , 2011, European journal of cancer.

[23]  Guido Marcucci,et al.  The prognostic and functional role of microRNAs in acute myeloid leukemia. , 2011, Blood.

[24]  Xi Chen,et al.  Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. , 2010, Clinical chemistry.

[25]  Wayne Tam,et al.  Accumulation of miR-155 and BIC RNA in human B cell lymphomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Tan,et al.  MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML , 2011, British journal of haematology.

[27]  Christian Langer,et al.  Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[29]  Vivek Jayaswal,et al.  miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death , 2012, Molecular Cancer.

[30]  Jian-yong Li,et al.  miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. , 2012, Carcinogenesis.

[31]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[32]  C. Bloomfield,et al.  Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine , 2010, Proceedings of the National Academy of Sciences.

[33]  K. Ghoshal,et al.  TGFβ mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3 , 2009, Oncogene.

[34]  Jie Dong,et al.  VCP/p97, Down-Regulated by microRNA-129-5p, Could Regulate the Progression of Hepatocellular Carcinoma , 2012, PloS one.

[35]  Xi Chen,et al.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Thomas Tuschl,et al.  Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. , 2008, Methods.

[37]  W. Tse,et al.  Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics , 2009, Journal of hematology & oncology.

[38]  Lei Zhang,et al.  Involvement of microRNA‐93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells , 2012, FEBS letters.

[39]  Avrum Spira,et al.  miR-129 regulates cell proliferation by downregulating Cdk6 expression. , 2010, Cell cycle.

[40]  George A Calin,et al.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. , 2008, Blood.

[41]  Shaoxiang Zhang,et al.  MicroRNAs play a role in the development of human hematopoietic stem cells , 2008, Journal of cellular biochemistry.

[42]  Aadel A. Chaudhuri,et al.  Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder , 2008, The Journal of experimental medicine.

[43]  F. Lo‐Coco,et al.  MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status , 2012, Journal of Hematology & Oncology.

[44]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[45]  M. Caligiuri,et al.  Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. , 2012, Blood.

[46]  Duan Ma,et al.  Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma , 2013, Head & neck.

[47]  M. Caligiuri,et al.  Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Jie Yang,et al.  MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8 , 2011, Oncogene.

[49]  L. Bullinger,et al.  The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML , 2013, Leukemia.

[50]  Jørgen Kjems,et al.  Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. , 2009, Cancer research.

[51]  Tyler E. Miller,et al.  Anti-microRNA-222 (Anti-miR-222) and -181B Suppress Growth of Tamoxifen-resistant Xenografts in Mouse by Targeting TIMP3 Protein and Modulating Mitogenic Signal* , 2011, The Journal of Biological Chemistry.

[52]  L. Kobzik,et al.  MicroRNA-181b regulates NF-κB-mediated vascular inflammation. , 2012, The Journal of clinical investigation.

[53]  Min Liu,et al.  MicroRNA‐181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas , 2012, IUBMB life.